adenomyosis. Endometriosis of uterus
Conditions
Interventions
Intervention 1: Intervention group: 20 randomly selected adenomyosis patients will be treated with letrozole 2.5 mg (Abourihan Pharmaceutical Company) daily orally, for 3 months. Letrozole , which is
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: patients aged 18-40 years who referred to Rasool Akram Hospital with adenomyosis and dysmenorria and heavy mensural bleeding not Taking hormonal drugs containing estrogen or progesterone for three month before no history malignancy in the genital tract or breast not breast feeding for three month before no liver or kidney or blood disease not previous history of deep vein thrombosis or pulmonary emboly not delivery in last 6 months not pregnant
Exclusion criteria
Exclusion criteria: history of malignancy in the genital tract hormon therapy in last three month any systemic disease endometrial ablation with thermal balloon or resectoscope
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual bleeding. Timepoint: start of drug- three month later. Method of measurement: each day pad count.;Menstrual pain. Timepoint: start of drug- three month later. Method of measurement: vas score (The Visual Analogue Scale). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Rokhgireh
Iran University of Medical Sciences
Outcome results
None listed